Exelixis | EXEL - أصول متداولة





أصول متداولة تغيير تاريخ
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Akebia Therapeutics USD 243.48M 9.47M 2026-03
Amgen USD 31.48B 2.42B 2026-03
AstraZeneca USD 29.61B 890M 2026-03
Bayer EUR 32.91B 30M 2025-12
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Cytokinetics USD 839.46M 77.51M 2026-03
Eisai JPY 840.88B 50.18B 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Esperion Therapeutics USD 459.46M 3.11M 2026-03
Exelixis USD 1.21B 234.65M 2026-03
Genmab DKK 2.88B 1.59B 2025-12
Glaxosmithkline GBP 23.59B 390.44M 2025-12
Incyte USD 5.48B 460.36M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
MacroGenics USD 219.94M 12.15M 2025-12
Merck USD 35.02B 8.5B 2026-03
Moderna USD 5.77B 774M 2026-03
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Novartis USD 26.61B 3.85B 2026-03
Pfizer USD 42.82B 76M 2026-03
Puma Biotechnology USD 143.58M 7M 2025-09
Sanofi EUR 30.95B 8.99B 2025-12
Takeda JPY 3.12T 195.82B 2025-12
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
Xencor USD 482.85M 116.97M 2026-03